Downgrades Buy Neutral X

BOLD Boundless Bio

Guggenheim

Initiated Buy X

BOLD Boundless Bio

Guggenheim

$24

Initiated Outperform X

BOLD Boundless Bio

Leerink Partners

$25

Initiated Overweight X

BOLD Boundless Bio

Piper Sandler

$20

Downgrades Neutral Sell X

BOLD Audentes Therapeutics

Citigroup

$28 $32

Reiterated Buy X

BOLD Audentes Therapeutics

H.C. Wainwright

$44 $48

Upgrades Neutral Buy X

BOLD Audentes Therapeutics

Chardan Capital Markets

$35 $40

Upgrades Neutral Buy X

BOLD Audentes Therapeutics

Guggenheim

Initiated Overweight X

BOLD Audentes Therapeutics

JP Morgan

$35

Reiterated Sell X

BOLD Audentes Therapeutics

B. Riley FBR

$20 $21

Downgrades Outperform Mkt Perform X

BOLD Audentes Therapeutics

William Blair

Reiterated Buy X

BOLD Audentes Therapeutics

H.C. Wainwright

$33 $29

Initiated Neutral X

BOLD Audentes Therapeutics

Guggenheim

Initiated Sell X

BOLD Audentes Therapeutics

B. Riley FBR

$20

Initiated Sell X

BOLD Audentes Therapeutics

Cowen

$20

Initiated Neutral X

BOLD Audentes Therapeutics

Citigroup

$40

Initiated Neutral X

BOLD Audentes Therapeutics

Chardan Capital Markets

$35

Initiated Neutral X

BOLD Audentes Therapeutics

Mizuho

$26

BOLD  Audentes Therapeutics, Inc.

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.